Limits...
miR-145 is differentially regulated by TGF-β1 and ischaemia and targets Disabled-2 expression and wnt/β-catenin activity.

Mayorga ME, Penn MS - J. Cell. Mol. Med. (2012)

Bottom Line: The effect of wnt/β-catenin signalling in the response to acute myocardial infarction (AMI) remains controversial.There was no significant Dab2 expression in sham-operated myocardium.Our data demonstrate a novel and critical role for miR-145 expression as a regulator of Dab2 expression and β-catenin activity in response to TGF-β(1) and hypoxia.

View Article: PubMed Central - PubMed

Affiliation: Skirball Laboratory for Cardiovascular Cellular Therapeutics, Cleveland, OH, USA.

Show MeSH

Related in: MedlinePlus

miR-145 expression in infarcted rat myocardium. Total RNA was isolated from dissected infarct border zones from sham (No MI, open bar) and 1 hr (black bar) after AMI. The expression of miR-145 was analyzed by qPCR (n = 5 per group). A dramatic decrease in miR-145 expression was seen 1 hr after AMI. Results are presented as mean ± S.D. (**P < 0.01, *P < 0.01 Student's t-test).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4365889&req=5

fig06: miR-145 expression in infarcted rat myocardium. Total RNA was isolated from dissected infarct border zones from sham (No MI, open bar) and 1 hr (black bar) after AMI. The expression of miR-145 was analyzed by qPCR (n = 5 per group). A dramatic decrease in miR-145 expression was seen 1 hr after AMI. Results are presented as mean ± S.D. (**P < 0.01, *P < 0.01 Student's t-test).

Mentions: To determine if miR-145 was responsible for the regulation of Dab2 in the heart in response to ischaemia, we quantified pri-miR-145 at 1 hr after LAD ligation. As shown in Figure 6, there is a significant level of pri-miR-145 in the heart at baseline that is rapidly and significantly decreased as early as 1 hr after AMI. These data are consistent with our findings in vitro with MSC and suggest that down-regulation of miR-145 in response to ischaemia results in an up-regulation of Dab2 protein in the heart.


miR-145 is differentially regulated by TGF-β1 and ischaemia and targets Disabled-2 expression and wnt/β-catenin activity.

Mayorga ME, Penn MS - J. Cell. Mol. Med. (2012)

miR-145 expression in infarcted rat myocardium. Total RNA was isolated from dissected infarct border zones from sham (No MI, open bar) and 1 hr (black bar) after AMI. The expression of miR-145 was analyzed by qPCR (n = 5 per group). A dramatic decrease in miR-145 expression was seen 1 hr after AMI. Results are presented as mean ± S.D. (**P < 0.01, *P < 0.01 Student's t-test).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4365889&req=5

fig06: miR-145 expression in infarcted rat myocardium. Total RNA was isolated from dissected infarct border zones from sham (No MI, open bar) and 1 hr (black bar) after AMI. The expression of miR-145 was analyzed by qPCR (n = 5 per group). A dramatic decrease in miR-145 expression was seen 1 hr after AMI. Results are presented as mean ± S.D. (**P < 0.01, *P < 0.01 Student's t-test).
Mentions: To determine if miR-145 was responsible for the regulation of Dab2 in the heart in response to ischaemia, we quantified pri-miR-145 at 1 hr after LAD ligation. As shown in Figure 6, there is a significant level of pri-miR-145 in the heart at baseline that is rapidly and significantly decreased as early as 1 hr after AMI. These data are consistent with our findings in vitro with MSC and suggest that down-regulation of miR-145 in response to ischaemia results in an up-regulation of Dab2 protein in the heart.

Bottom Line: The effect of wnt/β-catenin signalling in the response to acute myocardial infarction (AMI) remains controversial.There was no significant Dab2 expression in sham-operated myocardium.Our data demonstrate a novel and critical role for miR-145 expression as a regulator of Dab2 expression and β-catenin activity in response to TGF-β(1) and hypoxia.

View Article: PubMed Central - PubMed

Affiliation: Skirball Laboratory for Cardiovascular Cellular Therapeutics, Cleveland, OH, USA.

Show MeSH
Related in: MedlinePlus